Malignant melanoma is an aggressive and lethal form of skin cancer that is resistant to conventional radio- and chemotherapy ([@bib12]). Although melanoma accounts for only about 4% of all dermatological cancers, it is responsible for the deaths of more than 80% of skin cancer patients ([@bib22]). In the United States, people diagnosed with melanoma were estimated to be 76 250 in 2012 and 9180 were predicted to die from melanoma ([@bib28]). Patients with AJCC stage IV metastatic melanoma (MM) have a poor prognosis with a median survival of only 6--8 months ([@bib7]) and less than 15% of the patients live more than 5 years ([@bib1]). Therefore, it is necessary to find effective treatment regimens for patients with advanced melanoma by a better understanding of the factors involved in the progression and metastasis of melanoma.

[@bib25] showed that a 17-gene signature in primary solid tumours is associated with tumour metastasis and poor prognosis. One of these genes is deoxyhypusine synthase (*DHPS*) that encodes for an enzyme necessary for post-translational hypusination ([@bib34]). It was originally thought that only eukaryotic translation initiation factor 5A (EIF5A) was the substrate of DHPS ([@bib34]). However, the EIF5A2 isoform was later discovered as another candidate substrate of this enzyme ([@bib13]). Human EIF5A2 shares 83% amino-acid identity with its isoform EIF5A ([@bib6]).

Immunohistochemical analysis in colorectal carcinoma (CRC) revealed that EIF5A2 overexpression was significantly correlated with tumour metastasis and was also an independent predictor of shortened survival. Ectopic overexpression of EIF5A2 in CRC cells increased cell invasion and motility *in vitro* and tumour metastasis *in vivo* and also induced epithelial--mesenchymal transition (EMT) by upregulating mesenchymal markers such as vimentin and fibronectin and downregulating epithelial markers such as E-cadherin and *β*-catenin. The depletion of EIF5A2 expression, on the other hand, inhibited cell invasion and EMT ([@bib38]). Similarly, a tissue microarray (TMA) study showed a higher EIF5A2 protein expression in metastatic hepatocellular carcinoma (HCC) tumours compared with their matched primary HCC. Moreover, ectopic expression of EIF5A2 increased HCC cell invasion and migration *in vitro* and tumour metastasis *in vivo* in a mouse model. In addition, the same study indicated that EIF5A2 induced EMT by reducing the expression of E-cadherin and *β*-catenin and increasing the expression of N-cadherin, vimentin and *α*-smooth muscle actin (*α*-SMA) ([@bib31]).

Overexpression of EIF5A2 has also been shown to be associated with poor prognosis in colon ([@bib35]; [@bib38]), ovarian ([@bib36]), lung ([@bib15]), and bladder cancers ([@bib4]). The only study regarding the role of EIF5A in melanoma was done by [@bib18] who showed that inhibition of EIF5A suppressed melanoma growth, suggesting that EIF5A has an important role in melanoma development. However, to our knowledge, there is no information available on the role of EIF5A2 isoform in melanoma.

To investigate the role of EIF5A2 in melanoma development, we used TMA and immunohistochemistry to evaluate EIF5A2 expression in a large set of human melanocytic lesions at different stages and analysed the correlation between EIF5A2 expression and clinicopathological variables and patient survival. We found that positive EIF5A2 staining is significantly associated with melanoma progression and a worse patient survival, and that EIF5A2 expression is an independent prognostic factor for all and primary melanoma (PM) patients. We also demonstrated that EIF5A2 is a downstream target of Akt and EIF5A2 enhances the invasiveness of melanoma cells by increasing the gelatinolytic activity of matrix metalloproteinase-2 (MMP-2) and perhaps by inducing EMT.

Materials and methods
=====================

Patients and specimens
----------------------

Formalin-fixed, paraffin-embedded tissues from 28 human common acquired naevi (CAN), 49 dysplastic naevi (DN), 242 PMs and 140 MMs were used for our present study. All specimens were obtained from the 1990 to 1998 archives of the Department of Pathology, Vancouver General Hospital. The use of human skin tissues in this study was approved by the Clinical Research Ethics Board of the University of British Columbia and was performed in accordance with the Declaration of Helsinki guidelines.

Tissue microarray construction and immunohistochemistry of TMA
--------------------------------------------------------------

Tissue microarray construction and immunohistochemical staining was performed as previously described ([@bib9]; [@bib37]). Antigen retrieval was done by heating the slides at 95 °C for 30 min in 10 m[M]{.smallcaps} sodium citrate (pH 6.0). The rabbit primary antibody against EIF5A2 (1 : 100 dilution) was obtained from Sigma (St Louis, MO, USA). For blocking experiment, anti-EIF5A2 antibody was incubated with 10 times concentration of its synthetic immunogenic peptide (1 : 10; Biomatik, Cambridge, ON, Canada) at 4 °C overnight before immunohistochemical staining.

Evaluation of immunostaining
----------------------------

The EIF5A2 cytoplasmic staining in TMAs was examined blinded by two independent observers (including one dermatopathologist), one core at a time simultaneously, and a consensus score was reached at the time of scoring each core. Eukaryotic translation initiation factor 5A2 staining intensity was scored as 0, 1+, 2+ and 3+. The percentage of EIF5A2-positive cells was also scored into four categories: 1 (0--25%), 2 (26--50%), 3 (51--75%) and 4 (76--100%). The level of EIF5A2 staining was evaluated by immunoreactive score (IRS), which is calculated by multiplying the scores of staining intensity and the percentage of positive cells. On the basis of the IRS, EIF5A2 staining pattern was defined as 0, negative; and 1--12, positive ([@bib17]; [@bib3]). For phosphorylated Akt (p-Akt) staining, we categorised the staining of the original study ([@bib9]) into two groups: negative-to-moderate and strong.

Statistical analysis of TMA
---------------------------

Differences in demographics and clinical characteristics and expression levels of EIF5A2 were evaluated by *χ*^2^-test between patient subgroups. Survival time was calculated from the date of melanoma diagnosis to the date of death or last follow-up. The Kaplan--Meier method was used to evaluate the correlation between EIF5A2 expression and patient survival. Multivariate Cox proportional hazards regression models were performed to estimate hazard ratios and their 95% confidence intervals. A *P*-value of \<0.05 was considered significant, and all tests were two-sided. SPSS version 11.5 (SPSS Inc, Chicago, IL, USA) software was used for all analyses.

Cell culture, plasmid construction and transfection
---------------------------------------------------

Human melanoma cell lines were cultured as previously described ([@bib20]). Human melanocytes (MC) were obtained from ScienCell Research Laboratories (Carlsbad, CA, USA) and A375 cell line was obtained from American Type Culture Collection (Manassas, VA, USA). The EIF5A2 open reading frame was subcloned from pBluescriptR (ImaGegen, Berlin, Germany) into pCDNA3.1+ using PCR primers harbouring *Xba*I and *Hind*III restriction sites. The recombinant DNA was handled in accordance with the NIH guidelines. Overexpression plasmid was transfected by Effectene reagent (Qiagen, Mississauga, ON, Canada) according to the manufacturer\'s instructions. For siRNA transfection, cells were incubated with either non-silencing control siRNA (siC) or EIF5A2-specific siRNA (siEIF5A2, Qiagen) or MMP-2-specific siRNA (siMMP-2, Qiagen) using Silenfect transfection reagent (Bio-Rad, Mississauga, ON, Canada).

Western blot
------------

Western blot analysis was performed as described previously ([@bib20]). The following antibodies were used for western blot: rabbit antibody against EIF5A2 (1 : 250 dilution; Sigma), rabbit anti-phospho-Ser-473 of Akt (1 : 1000; Cell Signaling, Beverly, MA, USA), rabbit antibody against integrin-linked kinase (ILK;1 : 500 dilution; Cell Signaling), mouse antibody against PTEN (1 : 200 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit antibody against vimentin (1 : 500 dilution; Cell Signaling), rabbit antibody against *α*-SMA (1 : 250 dilution, Abcam, Toronto, ON, Canada), mouse antibody against fibronectin (1 : 1000 dilution; BD Biosciences, Mississauga, ON, Canada), mouse antibody against E-cadherin (1 : 1000 dilution; BD Biosciences), mouse antibody against N-cadherin (1 : 1000 dilution; BD Biosciences) and actin (1 : 1000 dilution; Sigma).

Real-time reverse transcription--PCR
------------------------------------

Total RNA was prepared by Trizol (Invitrogen, Burlington, ON, Canada) and reverse transcribed into cDNA with the SuperScript First-Strand Synthesis System (Invitrogen) according to the manufacturer\'s protocol. Real-time reverse transcription--PCR was performed with SYBR Green Master mix system (Applied Biosystems, Carlsbad, CA, USA). The sequences of EIF5A2 primers were 5′-CCCTGCTGACAGAAACTGGT-3′ (forward) and 5′-TTGCACACATGACAGACACC-3′ (reverse). The primers for *β*-actin were 5′-GCTCTTTTCCAGCCTTCCTT-3′ (forward) and 5′-CGGATGTCAACTTCACACTT-3′ (reverse).

Cell invasion assay and zymography
----------------------------------

Boyden chamber invasion assay and zymography were performed as previously described ([@bib20]).

FACS analysis
-------------

Cells were collected by trypsinisation and pelleted by centrifugation at 500 **g** for 5 min. Cell pellets were then resuspended in 1 ml of hypotonic fluorochrome buffer (0.1% Triton X-100, 0.1% sodium citrate) containing 25 *μ*g ml^−1^ of RNase A and 50 *μ*g ml^−1^ of propidium iodide (Sigma). After being incubated at 4 °C in the dark for 1 h, samples were analysed by EPICS XL-MCL flow cytometer (Beckman Coulter, Miami, FL, USA) to determine the percentage of subdiploid DNA. Cells in sub-G1 phase were regarded as apoptotic cells.

Cell proliferation assay
------------------------

Cells were transfected with either vector control or EIF5A2 overexpression plasmid. After 24, 48 and 72 h, cell proliferation was determined with the sulforhodamine B (SRB) assay. Briefly, after the medium was removed, cells were fixed with 10% trichloroacetic acid for 1 h at 4 °C. The cells were then washed with tap water, air dried and stained with 0.4% SRB (dissolved in 1% acetic acid) for 30 min at room temperature. The cells were destained with 1% acetic acid and air dried. For quantification, the cells were incubated with 10 m[M]{.smallcaps} Tris (pH 10.5) on a shaker for 20 min to dissolve the bound dye followed by colorimetric determination at 550 nm.

Results
=======

EIF5A2 mRNA and protein expression in melanoma cell lines
---------------------------------------------------------

To investigate the expression pattern of EIF5A2 in melanoma, we studied the EIF5A2 mRNA levels in eight melanoma cell lines and normal human epithelial MC. Six melanoma cell lines showed over two-fold increase of EIF5A2 mRNA expression when compared with normal MC ([Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}). We also examined the EIF5A2 protein level in nine melanoma cell lines and two different batches of normal human epithelial MC as well as HEK293 cells as control. Seven melanoma cell lines showed over two-fold increase of EIF5A2 protein expression compared with the controls ([Supplementary Figure S1B and C](#sup1){ref-type="supplementary-material"}).

Correlation between EIF5A2 expression and clinicopathological parameters
------------------------------------------------------------------------

A total of 713 melanocytic lesions were used for TMA construction. Because of loss of biopsy cores or insufficient cells present in the cores, 400 melanoma (251 cases in PM and 149 cases in MM) and 77 cases of naevi (28 CAN and 49 DN) could be evaluated for EIF5A2 staining ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). To verify the specificity of the antibody used for staining, we used the synthetic immunogenic peptide (Biomatik) against anti-EIF5A2 antibody and found that this peptide substantially blocked EIF5A2 staining. ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). The clinical features of melanoma patients are listed in [Table 1](#tbl1){ref-type="table"}. We analysed the expression level of EIF5A2 in tumours with different thickness and ulceration, as thickness and ulceration are well-known prognostic markers for patients with PM. Although positive EIF5A2 expression was detected in 90% of thick melanomas (\>2 mm), only 70% of thin melanomas (⩽2 mm) showed positive EIF5A2 expression (*P*\<0.001, *χ*^2^-test; [Table 1](#tbl1){ref-type="table"}). Positive EIF5A2 expression was detected in 94% of melanomas with ulceration compared with 75% of melanomas without ulceration (*P*=0.005, *χ*^2^-test; [Table 1](#tbl1){ref-type="table"}). Further, positive EIF5A2 expression was significantly higher in AJCC stage I--II melanomas compared with stage III--IV melanomas ([Table 1](#tbl1){ref-type="table"}). The correlation of EIF5A2-positive staining with tumour thickness and AJCC stages suggests that EIF5A2 has an important role in melanoma invasion.

Increased EIF5A2 expression correlates with melanoma progression
----------------------------------------------------------------

To investigate whether EIF5A2 expression is changed in melanocytic lesions, immunohistochemical staining was performed in TMA slides ([Figures 1A--D](#fig1){ref-type="fig"}). When we grouped the samples into negative and positive EIF5A2 staining, *χ*^2^-test indicated a significant increase of EIF5A2 expression as melanoma progressed from DN to PM and from PM to MM ([Figure 1E](#fig1){ref-type="fig"}).

Increased EIF5A2 expression correlates with poor patient survival
-----------------------------------------------------------------

The Kaplan--Meier survival analysis indicated that positive EIF5A2 staining inversely correlated with overall and disease-specific 5-year survival in all melanomas (*P*=0.001, log-rank test; [Figure 2A and B](#fig2){ref-type="fig"}). Both overall and disease-specific 5-year survival are also significantly worse for PM patients with positive EIF5A2 staining compared with those with negative EIF5A2 staining (*P*=0.001 and \<0.001, respectively, log-rank test; [Figures 2C and D](#fig2){ref-type="fig"}). When the PM cases were further divided into two subgroups according to tumour thickness, we found that positive EIF5A2 expression is significantly correlated with poor patient overall and disease-specific survival in low-risk melanoma patients (⩽2.0 mm, *P*=0.026 and 0.044, respectively, log-rank test; [Figure 2E and F](#fig2){ref-type="fig"}). Strikingly, no patients with tumours ⩽2 mm thick died within 5 years in EIF5A2-negative staining group ([Figures 2E and F](#fig2){ref-type="fig"}). In order to validate these data, we analysed another cohort of 63 low-risk melanoma patients and obtained very similar results ([Supplementary Figures S4](#sup1){ref-type="supplementary-material"}). However, EIF5A2 expression did not significantly correlate with patient survival of thick PMs (\>2.0 mm) or MMs (data not shown). In addition, we performed Cox regression multivariate analysis including EIF5A2 expression, age, gender, location, thickness, histological subtype and ulceration in PM patients. We also performed Cox regression multivariate analysis to study the effect of EIF5A2 expression in patient survival together with age, sex and AJCC in all melanoma patients. In both cases, EIF5A2 expression was indicated to be an independent prognostic factor of poor 5-year overall and disease-specific survival ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

EIF5A2 regulates cell invasion and MMP-2 activity
-------------------------------------------------

Increased ability of cells to invade is one of the hallmarks of cancer, resulting in higher metastatic potential of melanoma and shorter survival of melanoma patients ([@bib11]). To study the role of EIF5A2 in melanoma cell invasion, we used EIF5A2-specific siRNA to knockdown (KD) EIF5A2 expression and found that cell invasion was significantly reduced in EIF5A2-KD MMRU and A375 cells compared with siC-transfected cells (*P*=0.027 and 0.029, respectively, *t*-test; [Figure 3B](#fig3){ref-type="fig"} and [Supplementary Figure S5A](#sup1){ref-type="supplementary-material"}). We also transfected melanoma MMRU, A375, MMLH, SK-mel-3, SK-mel-28, SK-mel-31 and SK-mel-93 cells with EIF5A2 overexpression vector and found that cell invasion in these cell lines increased significantly compared with the vector control ([Figure 4B](#fig4){ref-type="fig"} and [Supplementary Figures S5B--F and S6B](#sup1){ref-type="supplementary-material"}, respectively). Out of these cell lines, MMRU (unpublished sequencing data from our lab), A375 ([@bib2]), SK-mel-28 and SK-mel-3 ([@bib14]) carry BRAFV600E mutation and SK-mel-31 ([@bib5]) carries NRASQ61K mutation. As MMP-2 was shown to have a crucial role in cell invasion ([@bib33]; [@bib20]), we then carried out the zymography assay to compare the activity of MMP-2 in EIF5A2-KD- or EIF5A2-overexpressing MMRU cells compared with respective controls. Matrix metalloproteinase-2 gelatinolytic activity was decreased in EIF5A2-KD cells ([Figure 3C](#fig3){ref-type="fig"}), whereas increased in EIF5A2-overexpressing MMRU cells ([Figure 4C](#fig4){ref-type="fig"}), compared with respective controls. We previously investigated the expression of MMP-2 in melanoma using TMA and found that MMP-2 expression is a prognostic marker for melanoma patients ([@bib26]). As the TMA for MMP-2 study contained 369 melanoma biopsies, which were also included in the current study, we combined the two data sets in order to analyse the correlation between MMP-2 and EIF5A2 expression. Our results showed a direct correlation between the positive staining of EIF5A2 and strong expression of MMP-2 (*P*=0.004, *χ*^2^-test; [Figure 4D](#fig4){ref-type="fig"}). Finally, in order to further determine the role of MMP-2 in EIF5A2-induced invasion, we performed a simultaneous KD of MMP-2 and overexpression of EIF5A2 in MMRU melanoma cell lines. The results showed that relative cell invasion decreased significantly compared with when cells were overexpressed with EIF5A2 alone ([Figure 4E](#fig4){ref-type="fig"}), suggesting that EIF5A2-induced invasion may be mediated at least in part through MMP-2.

EIF5A2 is a downstream target of PI3K/Akt in melanoma cell invasion
-------------------------------------------------------------------

We and others have reported that p-Akt has an important role in melanoma progression and invasion, and p-Akt levels inversely correlate with melanoma patient survival ([@bib10]; [@bib9]). As the TMA for p-Akt study contained 123 melanoma biopsies, which were also included in the current study, we were able to combine the two data sets to analyse the correlation between p-Akt and EIF5A2 expression. Our results showed that positive staining of EIF5A2 directly correlated with high expression of p-Akt. The percentage of strong p-Akt staining increased from 45% in negative EIF5A2 group to 70% in positive EIF5A2 group (*P*=0.026, *χ*^2^-test; [Figure 4F](#fig4){ref-type="fig"}). On the basis of these results, we then examined whether EIF5A2 regulates p-Akt expression or *vice versa*. Overexpression of EIF5A2 in MMRU and SK-mel-93 cells resulted in no change in p-Akt expression ([Figure 4A](#fig4){ref-type="fig"} and [Supplementary Figure S6A](#sup1){ref-type="supplementary-material"}), whereas treatment with a small molecule p-Akt inhibitor API1 led to inhibition of Akt phosphorylation and EIF5A2 expression, decreased melanoma cell invasion by 48% and 43%, as well as a decrease in MMP-2 activity in MMRU and SK-mel-93 melanoma cell lines compared with vehicle ([Figure 4](#fig4){ref-type="fig"} and [Supplementary Figure S6](#sup1){ref-type="supplementary-material"}). This suggests that EIF5A2 is a downstream target of p-Akt in PI3K pathway. As ILK has been shown to directly phosphorylate Akt at serine-473, we next examined whether ILK regulates EIF5A2 expression and melanoma cell invasion. We found that a decrease in ILK expression in ILK-KD MMRU cells led to a decrease in EIF5A2 and p-Akt expression as well as a decrease in melanoma cell invasion ([Figure 5A and B](#fig5){ref-type="fig"}), suggesting that EIF5A2 is a downstream target of ILK as expected. Further, qRT--PCR data showed that the EIF5A2 mRNA level was significantly decreased by 61% in ILK-KD MMRU cells compared with control ([Figure 5C](#fig5){ref-type="fig"}), indicating that EIF5A2 expression is regulated by ILK at transcriptional level.

PI3K is an upstream regulator of ILK and PI3K activity is negatively regulated by PTEN. In order to determine the relationship between EIF5A2 and PI3K, we overexpressed PTEN in the PTEN-null MMRU and A375 melanoma cell lines and found that EIF5A2 expression and melanoma cell invasion were decreased in PTEN-overexpressing cells ([Figure 5D and E](#fig5){ref-type="fig"}; [Supplementary Figure S7](#sup1){ref-type="supplementary-material"}), confirming that EIF5A2 is a downstream target of PI3K/ILK/Akt pathway. However, PTEN overexpression in MMRU cells did not change the protein expression level of ILK because PTEN has been shown to negatively regulate ILK activity ([@bib23]), which is indicated by a decrease in p-Akt expression ([Figure 5D](#fig5){ref-type="fig"}). Therefore, it is the activity of PI3K not necessarily its expression level that regulates EIF5A2.

EIF5A2 has no effect on apoptosis or cell proliferation in melanoma cell lines
------------------------------------------------------------------------------

We performed FACS analysis and SRB cell proliferation assay in order to determine the role of EIF5A2 in apoptosis and cell proliferation ([Supplementary Figure S8](#sup1){ref-type="supplementary-material"}). The level of apoptosis in cells overexpressing EIF5A2 was not significantly different from the control group in MMRU, MMLH and A375 cell lines ([Supplementary Figures S8A, D, and E](#sup1){ref-type="supplementary-material"}, respectively). EIF5A2 KD also did not have a significant effect on apoptosis in MMRU cells ([Supplementary Figure S8B](#sup1){ref-type="supplementary-material"}). Similarly, the results of the SRB cell proliferation assay showed that, cell proliferation was not significantly different in EIF5A2 overexpressed cells, compared with the control group in MMRU and A375 cells ([Supplementary Figures S8C and F](#sup1){ref-type="supplementary-material"}, respectively). There was also no significant difference in the level of UV-induced apoptosis between cells overexpressing EIF5A2 and the control MMRU cells ([Supplementary Figure S8A](#sup1){ref-type="supplementary-material"}). These results suggest that the observed role of EIF5A2 in regulating melanoma cell invasion is not because of its effect on cell proliferation or apoptosis.

EIF5A2 may induce EMT
---------------------

In order to investigate whether or not EIF5A2 induces EMT, western blot analysis was performed. Eukaryotic translation initiation factor 5A2-overexpressing MMRU cells showed an upregulation of mesenchymal markers such as vimentin, fibronectin and *α*-SMA and a downregulation of E-cadherin epithelial marker compared with the vector control ([Supplementary Figure S9](#sup1){ref-type="supplementary-material"}). These data suggest that EIF5A2 may induce EMT.

Discussion
==========

Elevated EIF5A2 activity has been observed in different types of human cancers ([@bib35]; [@bib4]; [@bib36]; [@bib31]; [@bib38]). In this study, we investigated the potential oncogenic role of EIF5A2 in melanoma. Our results showed that EIF5A2 mRNA and protein expression increased significantly in different melanoma cell lines compared with MC ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). This is consistent with the results obtained by [@bib31] who showed the upregulation of EIF5A2 expression in eight HCC cell lines compared with immortalised liver cell lines.

In order to better understand the role of EIF5A2 activity in melanoma progression, we investigated EIF5A2 expression in 459 cases of melanocytic lesions at different stages using an antibody specific for EIF5A2. Our results demonstrated that EIF5A2 expression is significantly increased during melanoma progression ([Figure 1](#fig1){ref-type="fig"}). These stage-specific expression patterns suggest that increased EIF5A2 may have a role in the transformation from DN to PM as well as progression from primary to MM. Further, EIF5A2 expression significantly correlated with tumour thickness and ulceration ([Table 1](#tbl1){ref-type="table"}) and is inversely correlated with overall and disease-specific 5-year survival of all and primary, especially low-risk (⩽2.0 mm) melanoma patients ([Figure 2](#fig2){ref-type="fig"}). Interestingly, in the low-risk melanoma patients, all deaths within 5 years occurred only in the positive EIF5A2 staining group that might be an indication of the clinical importance of EIF5A2 for this group of patients. Multivariate Cox regression analysis further indicated that positive EIF5A2 expression was an independent prognostic marker for melanoma.

To our knowledge, this is the first study to demonstrate that EIF5A2 has an important role in melanoma progression and patient survival. A few studies supported the oncogenic role of EIF5A2 in other types of cancers. It was previously shown that overexpression of EIF5A2 may be important in the acquisition of a metastatic phenotype of CRC ([@bib35]; [@bib38]). Similarly, in ovarian cancer, EIF5A2 protein expression was positively correlated with an ascending clinical stage of the tumour ([@bib13]). In addition, [@bib21] found that upregulated expression of EIF5A2 mRNA was associated with a higher risk of lymph node metastasis of gastric carcinomas. Further, overexpression of EIF5A2 in urothelial carcinomas is associated with acquisition of a poor prognostic phenotype, suggesting that the expression of EIF5A2, as detected by immunohistochemistry, is a prognostic marker for patient survival of urothelial carcinoma ([@bib4]). All these reports support the notion that increased expression of EIF5A2 may be involved in the invasive and metastatic processes, leading to poor patient survival of different types of human cancers.

Our data showed that EIF5A2 regulates melanoma cell invasion *in vitro* ([Figures 3B](#fig3){ref-type="fig"} and [4B](#fig4){ref-type="fig"}, and [Supplementary Figures S5 and S6B](#sup1){ref-type="supplementary-material"}). We also demonstrated that EIF5A2 overexpression in melanoma cells results in an upregulation of mesenchymal markers such as vimentin, fibronectin and *α*-SMA, and a downregulation of E-cadherin epithelial marker ([Supplementary Figure S9](#sup1){ref-type="supplementary-material"}), which suggests that EIF5A2 may promote invasion and metastasis by inducing EMT. Similarly, others demonstrated that EIF5A2 has an important role in HCC and CRC invasion and metastasis by inducing EMT, characterised by downregulation of E-cadherin and upregulation of fibronectin, N-cadherin, *α*-SMA and vimentin ([@bib31]; [@bib38]). We found that EIF5A2 enhances the gelatinolytic activity of MMP-2 ([Figures 3C](#fig3){ref-type="fig"} and [4C](#fig4){ref-type="fig"}). A previous study by [@bib33] showed that the number of MMP-2-positive cells increased with increasing atypia in different stages of melanocytic lesions, suggesting the involvement of MMP-2 expression in melanomagenesis. The stimulatory effect of EIF5A2 on MMP-2 activity may at least partially contribute to the increase of melanoma cell invasion ([Figure 4E](#fig4){ref-type="fig"}), and this is consistent with our TMA data showing the positive correlation between EIF5A2 expression and melanoma tumour thickness. These data may also explain our observation that increased EIF5A2 expression significantly correlates with a poorer 5-year survival of PM patients. However, one of the weaknesses of this study is the lack of *in vivo* data using preclinical mouse models in order to support the *in vitro* data on invasion and metastasis.

Our TMA data showed a direct correlation between positive staining of EIF5A2 and strong expression of p-Akt ([Figure 4F](#fig4){ref-type="fig"}). Further, the p-Akt inhibitor API1 downregulated EIF5A2 protein expression and melanoma cell invasion ([Figure 4](#fig4){ref-type="fig"} and [Supplementary Figure S6](#sup1){ref-type="supplementary-material"}), suggesting that EIF5A2 may be a downstream effector of p-Akt, which has a role in melanoma cell invasion. In addition, we previously found a significant correlation between strong p-Akt expression and tumour invasion and a poorer 5-year melanoma patient survival ([@bib9]), which is consistent with our present data for EIF5A2. The consistency between the two sets of TMA data further supports the possibility of EIF5A2 and p-Akt being in the same pathway.

Integrin-linked kinase and PTEN are well-known upstream regulators of p-Akt ([@bib9]). We have previously shown that the expression of ILK was correlated with tumour invasion in PMs ([@bib8]). The expression of PTEN, a negative regulator of Akt pathway, was reduced in melanomas, and loss of PTEN was shown to increase melanoma tumour growth *in vivo* ([@bib29]; [@bib32]). These results are consistent with our present finding that both ILK KD and PTEN overexpression lead to a decrease in EIF5A2 expression ([Figures 5A and D](#fig5){ref-type="fig"} and [Supplementary Figure S7](#sup1){ref-type="supplementary-material"}), further supporting that EIF5A2 is a downstream target of PI3K/Akt pathway.

There are many factors that regulate MMP-2 expression and activity. For example, NF-*κ*B is a transcription factor downstream of p-Akt ([@bib10]) regulating cancer progression and metastasis ([@bib30]). Activation of NF-*κ*B induces membrane type proteases (MT1-MMP), the activator of pro-MMP-2, which proteolytically cleaves to generate functionally active MMP-2 ([@bib27]). AP-2*α* is another transcription factor that deregulates several factors including MMP-2 ([@bib24]) and its loss predicts poor survival of melanoma patients ([@bib19]). Skp2 is an oncogene that is required for the degradation of tumour suppressor p27. Overexpression of Skp2 has been shown to upregulate the expression and activity of MMP-2 in lung cancer cells ([@bib16]). The above molecules could be possible mediators to regulate EIF5A2-induced gelatinolytic activity of MMP-2. We also showed that EIF5A2 mRNA expression decreased in ILK-KD cells compared with the control ([Figure 5C](#fig5){ref-type="fig"}). The exact mechanism of how PI3K/p-Akt regulates the expression of EIF5A2 is not yet clear and requires further investigation. However, it is possible that some transcription factors in the PI3K pathway are responsible for the transcriptional upregulation of EIF5A2.

Taken together, we showed that EIF5A2 expression is significantly increased with melanoma progression and the increased EIF5A2 expression correlates with a worse 5-year survival of melanoma patients in particular those with tumour thickness less than 2.0 mm. Further, our data for the first time demonstrate that EIF5A2 is a downstream target of PI3K/Akt, which has an important role in regulating melanoma cell invasion, suggesting that targeting EIF5A2 may provide a novel therapeutic approach for melanoma.
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![**EIF5A2 expression in CAN, DN, PMs and MMs.** (**A** and **C**) CAN with negative EIF5A2 staining. (**B** and **D**) MM with positive EIF5A2 staining. Bar=100 *μ*m. (**E**) Positive EIF5A2 expression is increased in MMs compared with CAN (*P*\<0.001), DN (*P*\<0.001), and PMs (*P*=0.044). Positive EIF5A2 expression is increased in PMs compared with CAN (*P*=0.009) and DN (*P*=0.001).](bjc2013688f1){#fig1}

![**Correlation between EIF5A2 expression and 5-year patient survival.** (**A** and **B**) Overall and disease-specific 5-year survival of all melanoma patients, respectively (*P*=0.001, log-rank test). (**C** and **D**) Overall and disease-specific 5-year survival of PM patients (*P*=0.001 and *P*\<0.001, respectively, log-rank test). (**E** and **F**) Overall and disease-specific 5-year survival of thin (⩽2 mm) melanoma patients (*P*=0.026 and 0.044, respectively, log-rank test).](bjc2013688f2){#fig2}

![**EIF5A2 KD inhibits melanoma cell invasion by reducing MMP-2 activity.** MMRU melanoma cell lines were transfected with either control siRNA (siC) or siEIF5A2. (**A**) Protein extracts were prepared 72 h after transfection and analysed for the expression of EIF5A2. The numbers below the blot indicate fold change of EIF5A2 expression level. (**B**) For Boyden chamber assay, 48 h after siRNA transfection, cells were suspended in serum-free medium and seeded on matrigel, incubated at 37 °C for 24 h, stained with crystal violet and quantified. \**P*\<0.05, Student\'s *t*-test. (**C**) Matrix metalloproteinase-2 activity determined by zymography, which was performed 48 h after transfection. Recombinant MMP-2 was used as a positive control. The numbers below the gel picture indicate fold change of MMP-2 activity.](bjc2013688f3){#fig3}

![**EIF5A2, a downstream target of p-Akt, regulates melanoma cell invasion.** (**A**) MMRU cells were transfected with vector control or EIF5A2 overexpression plasmid, or treated with 2.5 *μ*[M]{.smallcaps} of either API1 or DMSO for 48 h. Protein extracts were prepared and analysed for the expression of EIF5A2, p-Akt and total Akt by western blot analysis. (**B**) Boyden chamber assay was performed 24 h after transfection or API1 treatment. \**P*\<0.05, \*\**P*\<0.01, Student\'s *t*-test. (**C**) Matrix metalloproteinase-2 activity determined by zymography, which was performed 48 h after transfection or API1 treatment. Recombinant MMP-2 was used as a positive control. (**D**) Positive staining of EIF5A2 directly correlates with strong expression of MMP-2 in human melanomas (*n*=369; *P*=0.0024, *χ*^2^-test). (**E**) MMRU cells were transfected with either siC plus empty vector or EIF5A2 overexpression plasmid, or a combination of EIF5A2 overexpression plasmid and siMMP-2. Boyden chamber assay was performed 48 h after transfection. \*\**P*\<0.01, Student\'s *t*-test. (**F**) Positive staining of EIF5A2 directly correlates with strong expression of p-Akt in human melanomas (*n*=123, *P*=0.026, *χ*^2^-test).](bjc2013688f4){#fig4}

![**Integrin-linked kinase KD or PTEN overexpression decrease EIF5A2 expression and invasion in MMRU melanoma cells.** (**A**) Control or shILK-KD MMRU melanoma cells were subjected to western blot analysis and analysed for the expression of EIF5A2, p-Akt, total Akt and ILK. (**B**) Boyden chamber assay was performed 24 h after transfection. \**P*\<0.05, Student\'s *t*-test. (**C**) Quantitative RT--PCR analysis of EIF5A2 from total RNA extraction in control and shILK-KD MMRU cells. \*\*\**P*\<0.001, Student\'s *t*-test. (**D**) MMRU melanoma cells were transfected with either vector control or PTEN overexpression plasmid. Protein extracts were prepared 48 h after transfection and analysed for expression of EIF5A2, p-Akt, total Akt, ILK and PTEN by western blotting. (**E**) Boyden chamber assay was performed 24 h after transfection. \*\**P*\<0.01, Student\'s *t*-test.](bjc2013688f5){#fig5}

###### EIF5A2 staining and clinicopathological characteristics of 382 melanomas

                                              **EIF5A2 staining**                             
  ------------------------------------------- --------------------- ----------- ----- ------- ----------------------------------
  **All melanoma (*****n*****=382)**                                                          
  **Age, years**                                                                              
  ⩽60                                         161 (81.3)             37 (18.7)   198   0.552                0.458
  \>60                                        144 (78.3)             40 (21.7)   184                           
  **Sex**                                                                                     
  Male                                        191 (83.4)             38 (16.6)   229   0.834                0.361
  Female                                      122 (79.7)             31 (20.3)   153                           
  **AJCC stage**                                                                              
  I                                           88 (69.3)              39 (30.7)   127   4.046   0.044[a](#t1-fn2){ref-type="fn"}
  II                                          103 (89.6)             12 (10.4)   115                           
  III                                         48 (88.9)              6 (11.1)    54                            
  IV                                          74 (86.0)              12 (14.0)   86                            
  **Primary melanoma (*****n*****=242)**                                                      
  **Age, years**                                                                              
  ⩽61                                         95 (77.2)              28 (22.8)   123   0.429                0.512
  \>61                                        96 (80.7)              23 (19.3)   119                           
  **Sex**                                                                                     
  Male                                        105 (78.9)             28 (21.1)   133   0.000                1.000
  Female                                      86 (78.9)              23 (21.1)   109                           
  **Tumour thickness (mm)**                                                                   
  ⩽2                                          94 (70.1)              40 (29.9)   134   13.90               \<0.001
  \>2                                         97 (89.8)              11 (10.2)   108                           
  **Ulceration**                                                                              
  Absent                                      146 (75.3)             48 (24.7)   194   7.911                0.005
  Present                                     45 (93.7)               3 (6.3)    48                            
  **Subtype**                                                                                 
  Lentigo maligna                             26 (70.3)              11 (29.7)   37    2.828                0.419
  Superficial spreading                       69 (77.5)              20 (22.5)   89                            
  Nodular                                     35 (85.4)              6 (14.6)    41                            
  Unspecified                                 61 (81.3)              14 (18.7)   75                            
  **Site**[b](#t1-fn3){ref-type="fn"}                                                         
  Sun protected                               150 (79.8)             38 (20.2)   188   0.376                0.540
  Sun exposed                                 41 (76.0)              13 (24.0)   54                            
  **Metastatic melanoma (*****n*****=140)**                                                   
  **Age, years**                                                                              
  ⩽59                                         63 (86.3)              10 (13.7)   73    0.096                0.757
  \>59                                        59 (88.1)              8 (11.9)    67                            
  **Sex**                                                                                     
  Male                                        86 (89.6)              10 (10.4)   96    1.624                0.203
  Female                                      36 (81.8)              8 (18.2)    44                            

Abbreviation: AJCC=American Joint Committee on Cancer.

Comparison between AJCC stage I--II and III--IV, *χ*^2^-test.

Sun-protected sites: trunk, arm, leg and feet; sun-exposed sites: head and neck.
